Biology subjects

Qazi, B.

Publications and source records attributed to Qazi, B..

3 recordsLinked to original sources

bioRxiv2026

Host cell plasma membrane-derived vesicles efficiently inhibit in vitro Influenza A virus infection in a size-dependent manner

The influenza virus poses a significant global health threat due to its continuous evolution, immune evasion, and zoonotic spillover. The rise of drug resistance, reduced susceptibility to existing antiviral medications, and the limited effectiveness of annual vaccines underscore the need for new antiviral strategies. To infect, the influenza virus binds to sialic acid (SA)-containing molecules on host cell membranes through hemagglutinin (HA). Blocking this interaction represents a promising antiviral approach. Herein, we report that SA containing plasma membrane-derived vesicles (PMV) efficiently inhibits in vitro Influenza A virus (IAV) infection. Using orthogonal methods, we demonstrate that PMV derived from A549, MDCK, and HEK cells competitively bind to H1N1 (WSN) and H3N2 (X-31) IAV strains, block entry and infection in human respiratory epithelial cells in a dose-dependent manner, without causing significant toxicity. When the size of the vesicles was reduced through extrusion, the antiviral activity was enhanced, and this was found to be correlated with a size-dependent increase in hemagglutination inhibition and reduced IAV internalisation. Plasma membrane-derived vesicles may serve as a novel antiviral strategy against influenza virus infections due to their simple production method and conserved SA binding site on HA.

biochemistry↗

bioRxiv2025

Tryptophan-aspartic acid containing peptide analog from coronin 1 inhibits model membrane fusion and enveloped viral infection in cells

Membrane fusion is a crucial step in the infection cycle of an enveloped virus, and the development of fusion inhibitors could lead to broad-spectrum antivirals beyond the one-bug-one-drug paradigm. In our continued effort to design peptide-based fusion inhibitors that block fusion by modulating membrane physical properties rather than targeting viral proteins, we have designed a tryptophan-aspartic acid (WD) containing peptide analog, mGG21, from coronin 1. Coronin 1 has been implicated in preventing the fusion of live mycobacteria containing phagosomes with lysosomes. The mGG-21 displays around 60% inhibition in fusion pore formation (complete fusion) in model membranes by increasing the acyl chain ordering of the membrane, regardless of the cholesterol content of the membrane, unlike previously designed predecessors with 20-30 % inhibition activity. Further, we show that mGG-21 inhibits Influenza and Chikungunya virus infection in cellular models without exerting any toxicity. Taken together, our findings underscore the importance of WD repeats in designing broad-range viral fusion inhibitors.

biophysics↗

bioRxiv2024

Developing peptide-based fusion inhibitors as an antiviral strategy utilizing Coronin 1 as a template

Enveloped viruses can enter the host cells by endocytosis and subsequently fuse with the endosomal membranes, or fuse with the plasma membrane at the cell surface. The crucial stage of viral infection, regardless of the route taken to enter the host cell, is membrane fusion. The present work aims to develop a peptide-based fusion inhibitor that prevents membrane fusion by modifying the properties of the participating membranes, without targeting a protein. This would allow us to develop a fusion inhibitor that might work against a larger spectrum of enveloped viruses as it does not target any specific viral fusion protein. With this goal, we have designed a novel peptide by modifying a native sequence derived from coronin 1, a phagosomal protein, that helps to avoid lysosomal degradation of mycobacterium-loaded phagosomes. The designed peptide, mTG-23, inhibits [~] 30-40% fusion between small unilamellar vesicles containing varying amounts of cholesterol by modulating the biophysical properties of the participating bilayers. As a proof of principle, we have further demonstrated that the mTG-23 inhibits Influenza A virus infection in A549 and MDCK cells (with[~] EC50 of 20.45 {micro}M and 21.45 {micro}M, respectively), where viral envelope and endosomal membrane fusion is a crucial step. Through a gamut of biophysical and biochemical methods, we surmise that mTG-23 inhibits viral infection by inhibiting viral envelope and endosomal membrane fusion. We envisage that the proposed antiviral strategy can be extended to other viruses that employ a similar modus operandi, providing a novel pan-antiviral approach.

biophysics↗